{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["drug metabolism", "drug\u2013gut microbe interaction", "gut microbiota", "herbal medicine", "metabolic disorder"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "36293657", "DateCompleted": {"Year": "2022", "Month": "10", "Day": "28"}, "DateRevised": {"Year": "2023", "Month": "01", "Day": "19"}, "Article": {"ArticleDate": [{"Year": "2022", "Month": "10", "Day": "11"}], "Language": ["eng"], "ELocationID": ["13076", "10.3390/ijerph192013076"], "Journal": {"ISSN": "1660-4601", "JournalIssue": {"Volume": "19", "Issue": "20", "PubDate": {"Year": "2022", "Month": "Oct", "Day": "11"}}, "Title": "International journal of environmental research and public health", "ISOAbbreviation": "Int J Environ Res Public Health"}, "ArticleTitle": "Gut Microbiome: The Interplay of an \"Invisible Organ\" with Herbal Medicine and Its Derived Compounds in Chronic Metabolic Disorders.", "Abstract": {"AbstractText": ["Resembling a concealed \"organ\" in a holobiont, trillions of gut microbes play complex roles in the maintenance of homeostasis, including participating in drug metabolism. The conventional opinion is that most of any drug is metabolized by the host and that individual differences are principally due to host genetic factors. However, current evidence indicates that only about 60% of the individual differences in drug metabolism are attributable to host genetics. Although most common chemical drugs regulate the gut microbiota, the gut microbiota is also known to be involved in drug metabolism, like the host. Interestingly, many traditional herbal medicines and derived compounds are biotransformed by gut microbiota, manipulating the compounds' effects. Accordingly, the gut microbiota and its specified metabolic pathways can be deemed a promising target for promoting drug efficacy and safety. However, the evidence regarding causality and the corresponding mechanisms concerning gut microbiota and drug metabolism remains insufficient, especially regarding drugs used to treat metabolic disorders. Therefore, the present review aims to comprehensively summarize the bidirectional roles of gut microbiota in the effects of herbal medicine in metabolic diseases to provide vital clues for guiding the clinical application of precision medicine and personalized drug development."]}, "AuthorList": [{"Identifier": ["0000-0002-3179-9439"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Diagnostics, College of Korean Medicine, Dongguk University, Dongguk-Ro 32, Goyang 10326, Korea."}], "LastName": "Lim", "ForeName": "Dong-Woo", "Initials": "DW"}, {"Identifier": ["0000-0002-2034-7429"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Bioscience & Integrative Medicine, Daejeon University, 75, Daedeok-daero 176, Seo-gu, Daejeon 35235, Korea."}], "LastName": "Wang", "ForeName": "Jing-Hua", "Initials": "JH"}], "GrantList": [{"GrantID": "2020R1F1A1074155", "Agency": "National Research Foundation of Korea", "Country": ""}], "PublicationTypeList": ["Journal Article", "Review", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Int J Environ Res Public Health", "NlmUniqueID": "101238455", "ISSNLinking": "1660-4601"}, "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Gastrointestinal Microbiome"}, {"QualifierName": [], "DescriptorName": "Herbal Medicine"}, {"QualifierName": [], "DescriptorName": "Plants, Medicinal"}, {"QualifierName": [], "DescriptorName": "Phytotherapy"}, {"QualifierName": [], "DescriptorName": "Chronic Disease"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Metabolic Diseases"}], "CoiStatement": "The authors declare no conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Davenport E.R., Sanders J.G., Song S.J., Amato K.R., Clark A.G., Knight R. The human microbiome in evolution. BMC Biol. 2017;15:127. doi: 10.1186/s12915-017-0454-7.", "ArticleIdList": ["10.1186/s12915-017-0454-7", "PMC5744394", "29282061"]}, {"Citation": "Dominguez-Bello M.G., Godoy-Vitorino F., Knight R., Blaser M.J. Role of the microbiome in human development. Gut. 2019;68:1108\u20131114. doi: 10.1136/gutjnl-2018-317503.", "ArticleIdList": ["10.1136/gutjnl-2018-317503", "PMC6580755", "30670574"]}, {"Citation": "Farr\u00e9-Maduell E., Casals-Pascual C. The origins of gut microbiome research in Europe: From Escherich to Nissle. Hum. Microbiome J. 2019;14:100065. doi: 10.1016/j.humic.2019.100065.", "ArticleIdList": ["10.1016/j.humic.2019.100065"]}, {"Citation": "Satoor S.N., Patil D.P., Kristensen H.D., Joglekar M.V., Shouche Y., Hardikar A.A. Manipulation and assessment of gut microbiome for metabolic studies. Methods Mol. Biol. 2014;1194:449\u2013469. doi: 10.1007/978-1-4939-1215-5_26.", "ArticleIdList": ["10.1007/978-1-4939-1215-5_26", "25064120"]}, {"Citation": "Zhu B., Wang X., Li L. Human gut microbiome: The second genome of human body. Protein Cell. 2010;1:718\u2013725. doi: 10.1007/s13238-010-0093-z.", "ArticleIdList": ["10.1007/s13238-010-0093-z", "PMC4875195", "21203913"]}, {"Citation": "Sender R., Fuchs S., Milo R. Revised Estimates for the Number of Human and Bacteria Cells in the Body. PLoS Biol. 2016;14:e1002533. doi: 10.1371/journal.pbio.1002533.", "ArticleIdList": ["10.1371/journal.pbio.1002533", "PMC4991899", "27541692"]}, {"Citation": "D\u2019Argenio V., Salvatore F. The role of the gut microbiome in the healthy adult status. Clin. Chim. Acta. 2015;451:97\u2013102. doi: 10.1016/j.cca.2015.01.003.", "ArticleIdList": ["10.1016/j.cca.2015.01.003", "25584460"]}, {"Citation": "Dzherieva I., Volkova N., Panfilova N. Depressive disorders in males with metabolic syndrome. J. Biomed. Clin. Res. 2011;4:46\u201349."}, {"Citation": "Im H.J., Ahn Y.C., Wang J.H., Lee M.M., Son C.G. Systematic review on the prevalence of nonalcoholic fatty liver disease in South Korea. Clin. Res. Hepatol. Gastroenterol. 2021;45:101526. doi: 10.1016/j.clinre.2020.06.022.", "ArticleIdList": ["10.1016/j.clinre.2020.06.022", "32919911"]}, {"Citation": "Karalliedde J., Gnudi L. Diabetes mellitus, a complex and heterogeneous disease, and the role of insulin resistance as a determinant of diabetic kidney disease. Nephrol. Dial. Transplant. 2014;31:206\u2013213. doi: 10.1093/ndt/gfu405.", "ArticleIdList": ["10.1093/ndt/gfu405", "25550448"]}, {"Citation": "L\u00ea K.-A., Bortolotti M. Role of dietary carbohydrates and macronutrients in the pathogenesis of nonalcoholic fatty liver disease. Curr. Opin. Clin. Nutr. Metab. Care. 2008;11:477\u2013482. doi: 10.1097/MCO.0b013e328302f3ec.", "ArticleIdList": ["10.1097/MCO.0b013e328302f3ec", "18542010"]}, {"Citation": "Phelan S., Wadden T., Berkowitz R., Sarwer D., Womble L., Cato R., Rothman R. Impact of weight loss on the metabolic syndrome. Int. J. Obes. 2007;31:1442\u20131448. doi: 10.1038/sj.ijo.0803606.", "ArticleIdList": ["10.1038/sj.ijo.0803606", "17356528"]}, {"Citation": "Alley D.E., Chang V.W. Metabolic syndrome and weight gain in adulthood. J. Gerontol. Ser. A Biomed. Sci. Med. Sci. 2010;65:111\u2013117. doi: 10.1093/gerona/glp177.", "ArticleIdList": ["10.1093/gerona/glp177", "PMC2796886", "19906821"]}, {"Citation": "Franklin S.S., Barboza M.G., Pio J.R., Wong N.D. Blood pressure categories, hypertensive subtypes, and the metabolic syndrome. J. Hypertens. 2006;24:2009\u20132016. doi: 10.1097/01.hjh.0000244950.72664.02.", "ArticleIdList": ["10.1097/01.hjh.0000244950.72664.02", "16957561"]}, {"Citation": "Di Daniele N.J.N. Association of Dietary Patterns with Metabolic Syndrome. Volume 12. Multidisciplinary Digital Publishing Institute; Basel, Switzerland: 2020. p. 2840."}, {"Citation": "Halpern A., Mancini M.C., Magalh\u00e3es M.E.C., Fisberg M., Radominski R., Bertolami M.C., Bertolami A., de Melo M.E., Zanella M.T., Queiroz M.S.J.D., et al. Metabolic syndrome, dyslipidemia, hypertension and type 2 diabetes in youth: From diagnosis to treatment. Diabetol. Metab. Syndr. 2010;2:1\u201320. doi: 10.1186/1758-5996-2-55.", "ArticleIdList": ["10.1186/1758-5996-2-55", "PMC2939537", "20718958"]}, {"Citation": "Finsterer J., Frank M. Repurposed drugs in metabolic disorders. Curr. Top. Med. Chem. 2013;13:2386\u20132394. doi: 10.2174/15680266113136660166.", "ArticleIdList": ["10.2174/15680266113136660166", "24059459"]}, {"Citation": "Scotti L., Monteiro A.F.M., de Oliveira Viana J., Mendon\u00e7a Junior F.J.B., Ishiki H.M., Tchouboun E.N., Santos R., Scotti M.T. Multi-Target Drugs Against Metabolic Disorders. Endocr. Metab. Immune Disord. Drug Targets. 2019;19:402\u2013418. doi: 10.2174/1871530319666181217123357.", "ArticleIdList": ["10.2174/1871530319666181217123357", "30556507"]}, {"Citation": "Jang S., Jang B.-H., Ko Y., Sasaki Y., Park J.-S., Hwang E.-H., Song Y.-K., Shin Y.-C., Ko S.-G. Herbal Medicines for Treating Metabolic Syndrome: A Systematic Review of Randomized Controlled Trials. Evid. Based Complement. Altern. Med. 2016;2016:5936402. doi: 10.1155/2016/5936402.", "ArticleIdList": ["10.1155/2016/5936402", "PMC4930818", "27413388"]}, {"Citation": "Almazroo O.A., Miah M.K., Venkataramanan R. Drug Metabolism in the Liver. Clin. Liver Dis. 2017;21:1\u201320. doi: 10.1016/j.cld.2016.08.001.", "ArticleIdList": ["10.1016/j.cld.2016.08.001", "27842765"]}, {"Citation": "Zhao M., Ma J., Li M., Zhang Y., Jiang B., Zhao X., Huai C., Shen L., Zhang N., He L., et al. Cytochrome P450 Enzymes and Drug Metabolism in Humans. Int. J. Mol. Sci. 2021;22:12808. doi: 10.3390/ijms222312808.", "ArticleIdList": ["10.3390/ijms222312808", "PMC8657965", "34884615"]}, {"Citation": "Rath S., Rud T., Karch A., Pieper D.H., Vital M. Pathogenic functions of host microbiota. Microbiome. 2018;6:174. doi: 10.1186/s40168-018-0542-0.", "ArticleIdList": ["10.1186/s40168-018-0542-0", "PMC6162913", "30266099"]}, {"Citation": "Qin Y., Havulinna A.S., Liu Y., Jousilahti P., Ritchie S.C., Tokolyi A., Sanders J.G., Valsta L., Bro\u017cy\u0144ska M., Zhu Q. Combined effects of host genetics and diet on human gut microbiota and incident disease in a single population cohort. Nat. Genet. 2022;54:134\u2013142. doi: 10.1038/s41588-021-00991-z.", "ArticleIdList": ["10.1038/s41588-021-00991-z", "PMC9883041", "35115689"]}, {"Citation": "Kang C., Wang B., Kaliannan K., Wang X., Lang H., Hui S., Huang L., Zhang Y., Zhou M., Chen M. Gut microbiota mediates the protective effects of dietary capsaicin against chronic low-grade inflammation and associated obesity induced by high-fat diet. MBio. 2017;8:e00470-17. doi: 10.1128/mBio.00470-17.", "ArticleIdList": ["10.1128/mBio.00470-17", "PMC5442453", "28536285"]}, {"Citation": "Daly A.K. Genetic polymorphisms affecting drug metabolism: Recent advances and clinical aspects. Adv. Pharm. 2012;63:137\u2013167. doi: 10.1016/b978-0-12-398339-8.00004-5.", "ArticleIdList": ["10.1016/b978-0-12-398339-8.00004-5", "22776641"]}, {"Citation": "Noh K., Kang Y.R., Nepal M.R., Shakya R., Kang M.J., Kang W., Lee S., Jeong H.G., Jeong T.C. Impact of gut microbiota on drug metabolism: An update for safe and effective use of drugs. Arch. Pharm. Res. 2017;40:1345\u20131355. doi: 10.1007/s12272-017-0986-y.", "ArticleIdList": ["10.1007/s12272-017-0986-y", "29181640"]}, {"Citation": "Zgheib N.K., Branch R.A. Drug metabolism and liver disease: A drug-gene-environment interaction. Drug Metab. Rev. 2017;49:35\u201355. doi: 10.1080/03602532.2016.1271807.", "ArticleIdList": ["10.1080/03602532.2016.1271807", "27957864"]}, {"Citation": "Belle D.J., Singh H. Genetic factors in drug metabolism. Am. Fam. Physician. 2008;77:1553\u20131560.", "ArticleIdList": ["18581835"]}, {"Citation": "Pant A., Maiti T.K., Mahajan D., Das B. Human Gut Microbiota and Drug Metabolism. Microb. Ecol. 2022:1\u201315. doi: 10.1007/s00248-022-02081-x.", "ArticleIdList": ["10.1007/s00248-022-02081-x", "PMC9308113", "35869999"]}, {"Citation": "Zimmermann M., Zimmermann-Kogadeeva M., Wegmann R., Goodman A.L. Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature. 2019;570:462\u2013467. doi: 10.1038/s41586-019-1291-3.", "ArticleIdList": ["10.1038/s41586-019-1291-3", "PMC6597290", "31158845"]}, {"Citation": "An X., Bao Q., Di S., Zhao Y., Zhao S., Zhang H., Lian F., Tong X. The interaction between the gut Microbiota and herbal medicines. Biomed. Pharmacother. 2019;118:109252. doi: 10.1016/j.biopha.2019.109252.", "ArticleIdList": ["10.1016/j.biopha.2019.109252", "31545247"]}, {"Citation": "Koppel N., Maini Rekdal V., Balskus E.P. Chemical transformation of xenobiotics by the human gut microbiota. Science. 2017;356:eaag2770. doi: 10.1126/science.aag2770.", "ArticleIdList": ["10.1126/science.aag2770", "PMC5534341", "28642381"]}, {"Citation": "Hollman A. Plants and cardiac glycosides. Br. Heart J. 1985;54:258\u2013261. doi: 10.1136/hrt.54.3.258.", "ArticleIdList": ["10.1136/hrt.54.3.258", "PMC481893", "4041297"]}, {"Citation": "Leisegang K. Herbal Medicine in Andrology. Elsevier; Amsterdam, The Netherlands: 2021. Herbal pharmacognosy: An introduction; pp. 17\u201326."}, {"Citation": "Hollman P.C., Bijsman M.N., Van Gameren Y., Cnossen E.P., De Vries J.H., Katan M.B. The sugar moiety is a major determinant of the absorption of dietary flavonoid glycosides in man. Free Radic. Res. 1999;31:569\u2013573. doi: 10.1080/10715769900301141.", "ArticleIdList": ["10.1080/10715769900301141", "10630681"]}, {"Citation": "Bhattacharya A. Effect of High Temperature on Crop Productivity and Metabolism of Macro Molecules. Elsevier; London, UK: 2019. High-Temperature Stress and Metabolism of Secondary Metabolites in Plants; pp. 391\u2013484."}, {"Citation": "Kumar S., Pandey A.K. Chemistry and biological activities of flavonoids: An overview. Sci. World J. 2013;2013:162750. doi: 10.1155/2013/162750.", "ArticleIdList": ["10.1155/2013/162750", "PMC3891543", "24470791"]}, {"Citation": "Xu J., Chen H.B., Li S.L. Understanding the Molecular Mechanisms of the Interplay Between Herbal Medicines and Gut Microbiota. Med. Res. Rev. 2017;37:1140\u20131185. doi: 10.1002/med.21431.", "ArticleIdList": ["10.1002/med.21431", "28052344"]}, {"Citation": "Wilson I.D., Nicholson J.K. Gut microbiome interactions with drug metabolism, efficacy, and toxicity. Transl. Res. 2017;179:204\u2013222. doi: 10.1016/j.trsl.2016.08.002.", "ArticleIdList": ["10.1016/j.trsl.2016.08.002", "PMC5718288", "27591027"]}, {"Citation": "Feng W., Liu J., Ao H., Yue S., Peng C. Targeting gut microbiota for precision medicine: Focusing on the efficacy and toxicity of drugs. Theranostics. 2020;10:11278\u201311301. doi: 10.7150/thno.47289.", "ArticleIdList": ["10.7150/thno.47289", "PMC7532689", "33042283"]}, {"Citation": "Shi Z.Y., Zeng J.Z., Wong A.S.T. Chemical Structures and Pharmacological Profiles of Ginseng Saponins. Molecules. 2019;24:2443. doi: 10.3390/molecules24132443.", "ArticleIdList": ["10.3390/molecules24132443", "PMC6651355", "31277214"]}, {"Citation": "Kim D.H. Gut microbiota-mediated pharmacokinetics of ginseng saponins. J. Ginseng Res. 2018;42:255\u2013263. doi: 10.1016/j.jgr.2017.04.011.", "ArticleIdList": ["10.1016/j.jgr.2017.04.011", "PMC6026358", "29983606"]}, {"Citation": "Kim H., Lee J.H., Kim J.E., Kim Y.S., Ryu C.H., Lee H.J., Kim H.M., Jeon H., Won H.J., Lee J.Y., et al. Micro-/nano-sized delivery systems of ginsenosides for improved systemic bioavailability. J. Ginseng Res. 2018;42:361\u2013369. doi: 10.1016/j.jgr.2017.12.003.", "ArticleIdList": ["10.1016/j.jgr.2017.12.003", "PMC6026383", "29983618"]}, {"Citation": "Kim H.-K. Pharmacokinetics of ginsenoside Rb1 and its metabolite compound K after oral administration of Korean Red Ginseng extract. J. Ginseng Res. 2013;37:451. doi: 10.5142/jgr.2013.37.451.", "ArticleIdList": ["10.5142/jgr.2013.37.451", "PMC3825860", "24235859"]}, {"Citation": "Paek I.B., Moon Y., Kim J., Ji H.Y., Kim S.A., Sohn D.H., Kim J.B., Lee H.S. Pharmacokinetics of a ginseng saponin metabolite compound K in rats. Biopharm. Drug Dispos. 2006;27:39\u201345. doi: 10.1002/bdd.481.", "ArticleIdList": ["10.1002/bdd.481", "16302287"]}, {"Citation": "Jung I.H., Lee J.H., Hyun Y.J., Kim D.H. Metabolism of ginsenoside Rb1 by human intestinal microflora and cloning of its metabolizing beta-D-glucosidase from Bifidobacterium longum H-1. Biol. Pharm. Bull. 2012;35:573\u2013581. doi: 10.1248/bpb.35.573.", "ArticleIdList": ["10.1248/bpb.35.573", "22466563"]}, {"Citation": "Park S.Y., Bae E.A., Sung J.H., Lee S.K., Kim D.H. Purification and characterization of ginsenoside Rb1-metabolizing beta-glucosidase from Fusobacterium K-60, a human intestinal anaerobic bacterium. Biosci. Biotechnol. Biochem. 2001;65:1163\u20131169. doi: 10.1271/bbb.65.1163.", "ArticleIdList": ["10.1271/bbb.65.1163", "11440132"]}, {"Citation": "Quan L.H., Min J.W., Yang D.U., Kim Y.J., Yang D.C. Enzymatic biotransformation of ginsenoside Rb1 to 20(S)-Rg3 by recombinant beta-glucosidase from Microbacterium esteraromaticum. Appl. Microbiol. Biotechnol. 2012;94:377\u2013384. doi: 10.1007/s00253-011-3861-7.", "ArticleIdList": ["10.1007/s00253-011-3861-7", "22249721"]}, {"Citation": "Akao T., Kida H., Kanaoka M., Hattori M., Kobashi K. Drug metabolism: Intestinal bacterial hydrolysis is required for the appearance of compound K in rat plasma after oral administration of ginsenoside Rb1 from Panax ginseng. J. Pharm. Pharmacol. 1998;50:1155\u20131160. doi: 10.1111/j.2042-7158.1998.tb03327.x.", "ArticleIdList": ["10.1111/j.2042-7158.1998.tb03327.x", "9821663"]}, {"Citation": "Qian T., Cai Z., Wong R.N., Mak N.K., Jiang Z.H. In vivo rat metabolism and pharmacokinetic studies of ginsenoside Rg3. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2005;816:223\u2013232. doi: 10.1016/j.jchromb.2004.11.036.", "ArticleIdList": ["10.1016/j.jchromb.2004.11.036", "15664354"]}, {"Citation": "Bae E.-A., Choo M.-K., Park E.-K., Park S.-Y., Shin H.-Y., Kim D.-H. Metabolism of ginsenoside Rc by human intestinal bacteria and its related antiallergic activity. Biol. Pharm. Bull. 2002;25:743\u2013747. doi: 10.1248/bpb.25.743.", "ArticleIdList": ["10.1248/bpb.25.743", "12081140"]}, {"Citation": "Tawab M.A., Bahr U., Karas M., Wurglics M., Schubert-Zsilavecz M. Degradation of ginsenosides in humans after oral administration. Drug Metab. Dispos. 2003;31:1065\u20131071. doi: 10.1124/dmd.31.8.1065.", "ArticleIdList": ["10.1124/dmd.31.8.1065", "12867496"]}, {"Citation": "Hasegawa H. Anticarcinogenesis in mice by ginseng-hydrolyzing colonic bacteria. Microb. Ecol. Health Dis. 2000;12:85\u201391."}, {"Citation": "Hasegawa H., Sung J.H., Benno Y. Role of human intestinal Prevotella oris in hydrolyzing ginseng saponins. Planta Med. 1997;63:436\u2013440. doi: 10.1055/s-2006-957729.", "ArticleIdList": ["10.1055/s-2006-957729", "9342949"]}, {"Citation": "Prasain J.K., Peng N., Rajbhandari R., Wyss J.M. The Chinese Pueraria root extract (Pueraria lobata) ameliorates impaired glucose and lipid metabolism in obese mice. Phytomedicine. 2012;20:17\u201323. doi: 10.1016/j.phymed.2012.09.017.", "ArticleIdList": ["10.1016/j.phymed.2012.09.017", "PMC3513565", "23123226"]}, {"Citation": "Jung H.W., Kang A.N., Kang S.Y., Park Y.K., Song M.Y. The Root Extract of Pueraria lobata and Its Main Compound, Puerarin, Prevent Obesity by Increasing the Energy Metabolism in Skeletal Muscle. Nutrients. 2017;9:33. doi: 10.3390/nu9010033.", "ArticleIdList": ["10.3390/nu9010033", "PMC5295077", "28054981"]}, {"Citation": "Zhang Z., Lam T.N., Zuo Z. Radix Puerariae: An overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J. Clin. Pharmacol. 2013;53:787\u2013811. doi: 10.1002/jcph.96.", "ArticleIdList": ["10.1002/jcph.96", "23677886"]}, {"Citation": "Jin J.S., Nishihata T., Kakiuchi N., Hattori M. Biotransformation of C-glucosylisoflavone puerarin to estrogenic (3S)-equol in co-culture of two human intestinal bacteria. Biol. Pharm. Bull. 2008;31:1621\u20131625. doi: 10.1248/bpb.31.1621.", "ArticleIdList": ["10.1248/bpb.31.1621", "18670101"]}, {"Citation": "Zhang L., Pan Siu A.K., Lin G., Zuo Z. Intestinal absorbability of three Radix Puerariae isoflavones including daidzein, daidzin and puerarin. Chin. Med. 2011;6:41. doi: 10.1186/1749-8546-6-41.", "ArticleIdList": ["10.1186/1749-8546-6-41", "PMC3253046", "22108408"]}, {"Citation": "Park E.K., Shin J., Bae E.A., Lee Y.C., Kim D.H. Intestinal bacteria activate estrogenic effect of main constituents puerarin and daidzin of Pueraria thunbergiana. Biol. Pharm. Bull. 2006;29:2432\u20132435. doi: 10.1248/bpb.29.2432.", "ArticleIdList": ["10.1248/bpb.29.2432", "17142977"]}, {"Citation": "Shin J.E., Bae E.A., Lee Y.C., Ma J.Y., Kim D.H. Estrogenic effect of main components kakkalide and tectoridin of Puerariae Flos and their metabolites. Biol. Pharm. Bull. 2006;29:1202\u20131206. doi: 10.1248/bpb.29.1202.", "ArticleIdList": ["10.1248/bpb.29.1202", "16755017"]}, {"Citation": "Zhang G., Gong T., Kano Y., Yuan D. Screening for in vitro metabolites of kakkalide and irisolidone in human and rat intestinal bacteria by ultra-high performance liquid chromatography/quadrupole time-of-flight mass spectrometry. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2014;947\u2013948:117\u2013124. doi: 10.1016/j.jchromb.2013.12.017.", "ArticleIdList": ["10.1016/j.jchromb.2013.12.017", "24412694"]}, {"Citation": "Ran Q., Wang J., Wang L., Zeng H.-R., Yang X.-B., Huang Q.-W. Rhizoma coptidis as a Potential Treatment Agent for Type 2 Diabetes Mellitus and the Underlying Mechanisms: A Review. Front. Pharmacol. 2019;10:805. doi: 10.3389/fphar.2019.00805.", "ArticleIdList": ["10.3389/fphar.2019.00805", "PMC6661542", "31396083"]}, {"Citation": "Feng X., Wang K., Cao S., Ding L., Qiu F. Pharmacokinetics and Excretion of Berberine and Its Nine Metabolites in Rats. Front. Pharmacol. 2020;11:594852. doi: 10.3389/fphar.2020.594852.", "ArticleIdList": ["10.3389/fphar.2020.594852", "PMC7874128", "33584274"]}, {"Citation": "Dey P. Gut microbiota in phytopharmacology: A comprehensive overview of concepts, reciprocal interactions, biotransformations and mode of actions. Pharmacol. Res. 2019;147:104367. doi: 10.1016/j.phrs.2019.104367.", "ArticleIdList": ["10.1016/j.phrs.2019.104367", "31344423"]}, {"Citation": "Cheng H., Liu J., Tan Y., Feng W., Peng C. Interactions between gut microbiota and berberine, a necessary procedure to understand the mechanisms of berberine. J. Pharm. Anal. 2021;12:541\u2013555. doi: 10.1016/j.jpha.2021.10.003.", "ArticleIdList": ["10.1016/j.jpha.2021.10.003", "PMC9463479", "36105164"]}, {"Citation": "Zheng Y., Gou X., Zhang L., Gao H., Wei Y., Yu X., Pang B., Tian J., Tong X., Li M. Interactions Between Gut Microbiota, Host, and Herbal Medicines: A Review of New Insights Into the Pathogenesis and Treatment of Type 2 Diabetes. Front. Cell. Infect. Microbiol. 2020;10:360. doi: 10.3389/fcimb.2020.00360.", "ArticleIdList": ["10.3389/fcimb.2020.00360", "PMC7379170", "32766169"]}, {"Citation": "Feng R., Shou J.-W., Zhao Z.-X., He C.-Y., Ma C., Huang M., Fu J., Tan X.-S., Li X.-Y., Wen B.-Y. Transforming berberine into its intestine-absorbable form by the gut microbiota. Sci. Rep. 2015;5:1\u201315. doi: 10.1038/srep12155.", "ArticleIdList": ["10.1038/srep12155", "PMC4502414", "26174047"]}, {"Citation": "Li C., Ai G., Wang Y., Lu Q., Luo C., Tan L., Lin G., Liu Y., Li Y., Zeng H., et al. Oxyberberine, a novel gut microbiota-mediated metabolite of berberine, possesses superior anti-colitis effect: Impact on intestinal epithelial barrier, gut microbiota profile and TLR4-MyD88-NF-kappaB pathway. Pharm. Res. 2020;152:104603. doi: 10.1016/j.phrs.2019.104603.", "ArticleIdList": ["10.1016/j.phrs.2019.104603", "31863867"]}, {"Citation": "Baradaran Rahimi V., Askari V.R., Hosseinzadeh H. Promising influences of Scutellaria baicalensis and its two active constituents, baicalin, and baicalein, against metabolic syndrome: A review. Phytother. Res. 2021;35:3558\u20133574. doi: 10.1002/ptr.7046.", "ArticleIdList": ["10.1002/ptr.7046", "33590943"]}, {"Citation": "Kim D.-H., Jang I.-S., Lee H.-K., Jung E.-A., Lee K.-Y. Metabolism of glycyrrhizin and baicalin by human intestinal bacteria. Arch. Pharmacal Res. 1996;19:292\u2013296. doi: 10.1007/BF02976243.", "ArticleIdList": ["10.1007/BF02976243"]}, {"Citation": "Noh K., Kang Y., Nepal M.R., Jeong K.S., Oh D.G., Kang M.J., Lee S., Kang W., Jeong H.G., Jeong T.C. Role of Intestinal Microbiota in Baicalin-Induced Drug Interaction and Its Pharmacokinetics. Molecules. 2016;21:337. doi: 10.3390/molecules21030337.", "ArticleIdList": ["10.3390/molecules21030337", "PMC6273104", "26978333"]}, {"Citation": "Akao T., Kawabata K., Yanagisawa E., Ishihara K., Mizuhara Y., Wakui Y., Sakashita Y., Kobashi K. Balicalin, the predominant flavone glucuronide of scutellariae radix, is absorbed from the rat gastrointestinal tract as the aglycone and restored to its original form. J. Pharm. Pharmacol. 2000;52:1563\u20131568. doi: 10.1211/0022357001777621.", "ArticleIdList": ["10.1211/0022357001777621", "11197087"]}, {"Citation": "Taiming L., Xuehua J. Investigation of the absorption mechanisms of baicalin and baicalein in rats. J. Pharm. Sci. 2006;95:1326\u20131333. doi: 10.1002/jps.20593.", "ArticleIdList": ["10.1002/jps.20593", "16628739"]}, {"Citation": "Bak E.J., Kim J., Choi Y.H., Kim J.H., Lee D.E., Woo G.H., Cha J.H., Yoo Y.J. Wogonin ameliorates hyperglycemia and dyslipidemia via PPARalpha activation in db/db mice. Clin. Nutr. 2014;33:156\u2013163. doi: 10.1016/j.clnu.2013.03.013.", "ArticleIdList": ["10.1016/j.clnu.2013.03.013", "23623334"]}, {"Citation": "Xing S., Wang M., Peng Y., Li X. Effects of Intestinal Microecology on Metabolism and Pharmacokinetics of Oral Wogonoside and Baicalin. Nat. Prod. Commun. 2017;12:509\u2013514. doi: 10.1177/1934578X1701200412.", "ArticleIdList": ["10.1177/1934578X1701200412", "30520584"]}, {"Citation": "Ku S., Zheng H., Park M.S., Ji G.E. Optimization of \u03b2-glucuronidase activity from Lactobacillus delbrueckii Rh2 and and its use for biotransformation of baicalin and wogonoside. J. Korean Soc. Appl. Biol. Chem. 2011;54:275\u2013280. doi: 10.3839/jksabc.2011.043.", "ArticleIdList": ["10.3839/jksabc.2011.043"]}, {"Citation": "Kim H.S., Kim J.Y., Park M.S., Zheng H., Ji G.E. Cloning and expression of beta-glucuronidase from Lactobacillus brevis in E. coli and application in the bioconversion of baicalin and wogonoside. J. Microbiol. Biotechnol. 2009;19:1650\u20131655. doi: 10.4014/jmb.0904.04053.", "ArticleIdList": ["10.4014/jmb.0904.04053", "20075633"]}, {"Citation": "Shao W., Yu Z., Chiang Y., Yang Y., Chai T., Foltz W., Lu H., Fantus I.G., Jin T. Curcumin prevents high fat diet induced insulin resistance and obesity via attenuating lipogenesis in liver and inflammatory pathway in adipocytes. PLoS ONE. 2012;7:e28784. doi: 10.1371/journal.pone.0028784.", "ArticleIdList": ["10.1371/journal.pone.0028784", "PMC3253779", "22253696"]}, {"Citation": "Feng D., Zou J., Su D., Mai H., Zhang S., Li P., Zheng X. Curcumin prevents high-fat diet-induced hepatic steatosis in ApoE(-/-) mice by improving intestinal barrier function and reducing endotoxin and liver TLR4/NF-kappaB inflammation. Nutr. Metab. 2019;16:79. doi: 10.1186/s12986-019-0410-3.", "ArticleIdList": ["10.1186/s12986-019-0410-3", "PMC6858759", "31788011"]}, {"Citation": "Aggarwal B.B., Deb L., Prasad S. Curcumin differs from tetrahydrocurcumin for molecular targets, signaling pathways and cellular responses. Molecules. 2014;20:185\u2013205. doi: 10.3390/molecules20010185.", "ArticleIdList": ["10.3390/molecules20010185", "PMC6272158", "25547723"]}, {"Citation": "Lopresti A.L. The Problem of Curcumin and Its Bioavailability: Could Its Gastrointestinal Influence Contribute to Its Overall Health-Enhancing Effects? Adv. Nutr. 2018;9:41\u201350. doi: 10.1093/advances/nmx011.", "ArticleIdList": ["10.1093/advances/nmx011", "PMC6333932", "29438458"]}, {"Citation": "Burapan S., Kim M., Han J. Curcuminoid demethylation as an alternative metabolism by human intestinal microbiota. J. Agric. Food Chem. 2017;65:3305\u20133310. doi: 10.1021/acs.jafc.7b00943.", "ArticleIdList": ["10.1021/acs.jafc.7b00943", "28401758"]}, {"Citation": "Tan S., Rupasinghe T.W., Tull D.L., Boughton B., Oliver C., McSweeny C., Gras S.L., Augustin M.A. Degradation of curcuminoids by in vitro pure culture fermentation. J. Agric. Food Chem. 2014;62:11005\u201311015. doi: 10.1021/jf5031168.", "ArticleIdList": ["10.1021/jf5031168", "25317751"]}, {"Citation": "Dai X., Ding Y., Zhang Z., Cai X., Li Y. Quercetin and quercitrin protect against cytokineinduced injuries in RINm5F beta-cells via the mitochondrial pathway and NF-kappaB signaling. Int. J. Mol. Med. 2013;31:265\u2013271. doi: 10.3892/ijmm.2012.1177.", "ArticleIdList": ["10.3892/ijmm.2012.1177", "23138875"]}, {"Citation": "Babaei F., Mirzababaei M., Nassiri-Asl M. Quercetin in Food: Possible Mechanisms of Its Effect on Memory. J. Food Sci. 2018;83:2280\u20132287. doi: 10.1111/1750-3841.14317.", "ArticleIdList": ["10.1111/1750-3841.14317", "30103275"]}, {"Citation": "Kim D.H., Kim S.Y., Park S.Y., Han M.J. Metabolism of quercitrin by human intestinal bacteria and its relation to some biological activities. Biol. Pharm. Bull. 1999;22:749\u2013751. doi: 10.1248/bpb.22.749.", "ArticleIdList": ["10.1248/bpb.22.749", "10443478"]}, {"Citation": "Enkhmaa B., Shiwaku K., Katsube T., Kitajima K., Anuurad E., Yamasaki M., Yamane Y. Mulberry (Morus alba L.) leaves and their major flavonol quercetin 3-(6-malonylglucoside) attenuate atherosclerotic lesion development in LDL receptor-deficient mice. J. Nutr. 2005;135:729\u2013734. doi: 10.1093/jn/135.4.729.", "ArticleIdList": ["10.1093/jn/135.4.729", "15795425"]}, {"Citation": "Hirooka K., Fujita Y. Excess production of Bacillus subtilis quercetin 2,3-dioxygenase affects cell viability in the presence of quercetin. Biosci. Biotechnol. Biochem. 2010;74:1030\u20131038. doi: 10.1271/bbb.90928.", "ArticleIdList": ["10.1271/bbb.90928", "20460727"]}, {"Citation": "PARK S.-Y., KIM J.-H., KIM D.-H. Purification and characterization of quercitrin-hydrolyzing \u03b1-L-rhamnosidase from Fusobacterium K-60, a human intestinal bacterium. J. Microbiol. Biotechnol. 2005;15:519\u2013524."}, {"Citation": "Hosseini A., Razavi B.M., Banach M., Hosseinzadeh H. Quercetin and metabolic syndrome: A review. Phytother. Res. 2021;35:5352\u20135364. doi: 10.1002/ptr.7144.", "ArticleIdList": ["10.1002/ptr.7144", "34101925"]}, {"Citation": "Comalada M., Camuesco D., Sierra S., Ballester I., Xaus J., Galvez J., Zarzuelo A. In vivo quercitrin anti-inflammatory effect involves release of quercetin, which inhibits inflammation through down-regulation of the NF-kappaB pathway. Eur. J. Immunol. 2005;35:584\u2013592. doi: 10.1002/eji.200425778.", "ArticleIdList": ["10.1002/eji.200425778", "15668926"]}, {"Citation": "Graebin C.S. The pharmacological activities of glycyrrhizinic acid (\u201cglycyrrhizin\u201d) and glycyrrhetinic acid. Sweeteners. 2018:245."}, {"Citation": "Kwon Y.J., Son D.H., Chung T.H., Lee Y.J. A Review of the Pharmacological Efficacy and Safety of Licorice Root from Corroborative Clinical Trial Findings. J. Med. Food. 2020;23:12\u201320. doi: 10.1089/jmf.2019.4459.", "ArticleIdList": ["10.1089/jmf.2019.4459", "31874059"]}, {"Citation": "Yamamura Y., Santa T., Kotaki H., Uchino K., Sawada Y., Iga T. Administration-route dependency of absorption of glycyrrhizin in rats: Intraperitoneal administration dramatically enhanced bioavailability. Biol. Pharm. Bull. 1995;18:337\u2013341. doi: 10.1248/bpb.18.337.", "ArticleIdList": ["10.1248/bpb.18.337", "7742809"]}, {"Citation": "Akao T. Differences in the metabolism of glycyrrhizin, glycyrrhetic acid and glycyrrhetic acid monoglucuronide by human intestinal flora. Biol. Pharm. Bull. 2000;23:1418\u20131423. doi: 10.1248/bpb.23.1418.", "ArticleIdList": ["10.1248/bpb.23.1418", "11145169"]}, {"Citation": "Shin H.Y., Lee J.H., Lee J.Y., Han Y.O., Han M.J., Kim D.H. Purification and characterization of ginsenoside Ra-hydrolyzing beta-D-xylosidase from Bifidobacterium breve K-110, a human intestinal anaerobic bacterium. Biol. Pharm. Bull. 2003;26:1170\u20131173. doi: 10.1248/bpb.26.1170.", "ArticleIdList": ["10.1248/bpb.26.1170", "12913270"]}, {"Citation": "Nakamura K., Zhu S., Komatsu K., Hattori M., Iwashima M. Deglycosylation of the Isoflavone C-Glucoside Puerarin by a Combination of Two Recombinant Bacterial Enzymes and 3-Oxo-Glucose. Appl. Env. Microbiol. 2020;86:e00607-20. doi: 10.1128/AEM.00607-20.", "ArticleIdList": ["10.1128/AEM.00607-20", "PMC7357486", "32385077"]}, {"Citation": "Matthies A., Blaut M., Braune A. Isolation of a human intestinal bacterium capable of daidzein and genistein conversion. Appl. Environ. Microbiol. 2009;75:1740\u20131744. doi: 10.1128/AEM.01795-08.", "ArticleIdList": ["10.1128/AEM.01795-08", "PMC2655447", "19139227"]}, {"Citation": "Tan X.S., Ma J.Y., Feng R., Ma C., Chen W.J., Sun Y.P., Fu J., Huang M., He C.Y., Shou J.W., et al. Tissue distribution of berberine and its metabolites after oral administration in rats. PLoS ONE. 2013;8:e77969. doi: 10.1371/journal.pone.0077969.", "ArticleIdList": ["10.1371/journal.pone.0077969", "PMC3815028", "24205048"]}, {"Citation": "Hassaninasab A., Hashimoto Y., Tomita-Yokotani K., Kobayashi M. Discovery of the curcumin metabolic pathway involving a unique enzyme in an intestinal microorganism. Proc. Natl. Acad. Sci. USA. 2011;108:6615\u20136620. doi: 10.1073/pnas.1016217108.", "ArticleIdList": ["10.1073/pnas.1016217108", "PMC3080977", "21467222"]}, {"Citation": "Akao T. Purification and characterization of glycyrrhetic acid mono-glucuronide beta-D-glucuronidase in Eubacterium sp. GLH. Biol. Pharm. Bull. 1999;22:80\u201382. doi: 10.1248/bpb.22.80.", "ArticleIdList": ["10.1248/bpb.22.80", "9989667"]}, {"Citation": "Yim J.S., Kim Y.S., Moon S.K., Cho K.H., Bae H.S., Kim J.J., Park E.K., Kim D.H. Metabolic activities of ginsenoside Rb1, baicalin, glycyrrhizin and geniposide to their bioactive compounds by human intestinal microflora. Biol. Pharm. Bull. 2004;27:1580\u20131583. doi: 10.1248/bpb.27.1580.", "ArticleIdList": ["10.1248/bpb.27.1580", "15467199"]}, {"Citation": "Akao T. Influence of various bile acids on the metabolism of glycyrrhizin and glycyrrhetic acid by Ruminococcus sp. PO1-3 of human intestinal bacteria. Biol. Pharm. Bull. 1999;22:787\u2013793. doi: 10.1248/bpb.22.787.", "ArticleIdList": ["10.1248/bpb.22.787", "10480314"]}, {"Citation": "Chen X.J., Liu W.J., Wen M.L., Liang H., Wu S.M., Zhu Y.Z., Zhao J.Y., Dong X.Q., Li M.G., Bian L., et al. Ameliorative effects of Compound K and ginsenoside Rh1 on nonalcoholic fatty liver disease in rats. Sci. Rep. 2017;7:41144. doi: 10.1038/srep41144.", "ArticleIdList": ["10.1038/srep41144", "PMC5247696", "28106137"]}, {"Citation": "Li W., Zhang M., Gu J., Meng Z.J., Zhao L.C., Zheng Y.N., Chen L., Yang G.L. Hypoglycemic effect of protopanaxadiol-type ginsenosides and compound K on Type 2 diabetes mice induced by high-fat diet combining with streptozotocin via suppression of hepatic gluconeogenesis. Fitoterapia. 2012;83:192\u2013198. doi: 10.1016/j.fitote.2011.10.011.", "ArticleIdList": ["10.1016/j.fitote.2011.10.011", "22056666"]}, {"Citation": "Kim M.H., Park J.S., Jung J.W., Byun K.W., Kang K.S., Lee Y.S. Daidzein supplementation prevents nonalcoholic fatty liver disease through alternation of hepatic gene expression profiles and adipocyte metabolism. Int. J. Obes. 2011;35:1019\u20131030. doi: 10.1038/ijo.2010.256.", "ArticleIdList": ["10.1038/ijo.2010.256", "21157426"]}, {"Citation": "Spinozzi S., Colliva C., Camborata C., Roberti M., Ianni C., Neri F., Calvarese C., Lisotti A., Mazzella G., Roda A. Berberine and its metabolites: Relationship between physicochemical properties and plasma levels after administration to human subjects. J. Nat. Prod. 2014;77:766\u2013772. doi: 10.1021/np400607k.", "ArticleIdList": ["10.1021/np400607k", "24593257"]}, {"Citation": "Kang M.J., Ko G.S., Oh D.G., Kim J.S., Noh K., Kang W., Yoon W.K., Kim H.C., Jeong H.G., Jeong T.C. Role of metabolism by intestinal microbiota in pharmacokinetics of oral baicalin. Arch. Pharm. Res. 2014;37:371\u2013378. doi: 10.1007/s12272-013-0179-2.", "ArticleIdList": ["10.1007/s12272-013-0179-2", "23771520"]}, {"Citation": "Murugan P., Pari L. Influence of tetrahydrocurcumin on erythrocyte membrane bound enzymes and antioxidant status in experimental type 2 diabetic rats. J. Ethnopharmacol. 2007;113:479\u2013486. doi: 10.1016/j.jep.2007.07.004.", "ArticleIdList": ["10.1016/j.jep.2007.07.004", "17693046"]}, {"Citation": "Nakagawa K., Zingg J.M., Kim S.H., Thomas M.J., Dolnikowski G.G., Azzi A., Miyazawa T., Meydani M. Differential cellular uptake and metabolism of curcuminoids in monocytes/macrophages: Regulatory effects on lipid accumulation. Br. J. Nutr. 2014;112:8\u201314. doi: 10.1017/S0007114514000567.", "ArticleIdList": ["10.1017/S0007114514000567", "24725345"]}, {"Citation": "Dai X., Ding Y., Zhang Z., Cai X., Bao L., Li Y. Quercetin but not quercitrin ameliorates tumor necrosis factor-alpha-induced insulin resistance in C2C12 skeletal muscle cells. Biol. Pharm. Bull. 2013;36:788\u2013795. doi: 10.1248/bpb.b12-00947.", "ArticleIdList": ["10.1248/bpb.b12-00947", "23439570"]}, {"Citation": "Takeda S., Ishthara K., Wakui Y., Amagaya S., Maruno M., Akao T., Kobashi K. Bioavailability study of glycyrrhetic acid after oral administration of glycyrrhizin in rats; relevance to the intestinal bacterial hydrolysis. J. Pharm. Pharmacol. 1996;48:902\u2013905. doi: 10.1111/j.2042-7158.1996.tb05998.x.", "ArticleIdList": ["10.1111/j.2042-7158.1996.tb05998.x", "8910850"]}, {"Citation": "Park M., Lee J.H., Choi J.K., Hong Y.D., Bae I.H., Lim K.M., Park Y.H., Ha H. 18\u03b2-glycyrrhetinic acid attenuates anandamide-induced adiposity and high-fat diet induced obesity. Mol. Nutr. Food Res. 2014;58:1436\u20131446. doi: 10.1002/mnfr.201300763.", "ArticleIdList": ["10.1002/mnfr.201300763", "24687644"]}, {"Citation": "Yan T., Wang H., Cao L., Wang Q., Takahashi S., Yagai T., Li G., Krausz K.W., Wang G., Gonzalez F.J., et al. Glycyrrhizin Alleviates Nonalcoholic Steatohepatitis via Modulating Bile Acids and Meta-Inflammation. Drug Metab. Dispos. 2018;46:1310\u20131319. doi: 10.1124/dmd.118.082008.", "ArticleIdList": ["10.1124/dmd.118.082008", "PMC6081736", "29959134"]}, {"Citation": "Kim K.A., Jung I.H., Park S.H., Ahn Y.T., Huh C.S., Kim D.H. Comparative analysis of the gut microbiota in people with different levels of ginsenoside Rb1 degradation to compound K. PLoS ONE. 2013;8:e62409. doi: 10.1371/journal.pone.0062409.", "ArticleIdList": ["10.1371/journal.pone.0062409", "PMC3639287", "23638073"]}, {"Citation": "Matsumoto M., Ishige A., Yazawa Y., Kondo M., Muramatsu K., Watanabe K. Promotion of intestinal peristalsis by Bifidobacterium spp. capable of hydrolysing sennosides in mice. PLoS ONE. 2012;7:e31700. doi: 10.1371/journal.pone.0031700.", "ArticleIdList": ["10.1371/journal.pone.0031700", "PMC3284505", "22384059"]}, {"Citation": "Brooks A.W., Priya S., Blekhman R., Bordenstein S.R. Gut microbiota diversity across ethnicities in the United States. PLoS Biol. 2018;16:e2006842. doi: 10.1371/journal.pbio.2006842.", "ArticleIdList": ["10.1371/journal.pbio.2006842", "PMC6279019", "30513082"]}, {"Citation": "Kim C.Y., Lee M., Yang S., Kim K., Yong D., Kim H.R., Lee I. Human reference gut microbiome catalog including newly assembled genomes from under-represented Asian metagenomes. Genome Med. 2021;13:1\u201320. doi: 10.1186/s13073-021-00950-7.", "ArticleIdList": ["10.1186/s13073-021-00950-7", "PMC8394144", "34446072"]}, {"Citation": "Zhang X., Zhao Y., Zhang M., Pang X., Xu J., Kang C., Li M., Zhang C., Zhang Z., Zhang Y. Structural changes of gut microbiota during berberine-mediated prevention of obesity and insulin resistance in high-fat diet-fed rats. PLoS ONE. 2012;7:e42529. doi: 10.1371/journal.pone.0042529.", "ArticleIdList": ["10.1371/journal.pone.0042529", "PMC3411811", "22880019"]}, {"Citation": "Zhang B., Sun W., Yu N., Sun J., Yu X., Li X., Xing Y., Yan D., Ding Q., Xiu Z., et al. Anti-diabetic effect of baicalein is associated with the modulation of gut microbiota in streptozotocin and high-fat-diet induced diabetic rats. J. Funct. Foods. 2018;46:256\u2013267. doi: 10.1016/j.jff.2018.04.070.", "ArticleIdList": ["10.1016/j.jff.2018.04.070"]}, {"Citation": "Cani P.D., Delzenne N.M. The role of the gut microbiota in energy metabolism and metabolic disease. Curr. Pharm. Des. 2009;15:1546\u20131558. doi: 10.2174/138161209788168164.", "ArticleIdList": ["10.2174/138161209788168164", "19442172"]}, {"Citation": "Ansari M.H.R., Saher S., Parveen R., Khan W., Khan I.A., Ahmad S. Role of gut microbiota metabolism and biotransformation on dietary natural products to human health implications with special reference to biochemoinformatics approach. J. Tradit. Complement. Med. 2022 doi: 10.1016/j.jtcme.2022.03.005.", "ArticleIdList": ["10.1016/j.jtcme.2022.03.005"]}, {"Citation": "Oliphant K., Allen-Vercoe E. Macronutrient metabolism by the human gut microbiome: Major fermentation by-products and their Impact on host health. Microbiome. 2019;7:1\u201315. doi: 10.1186/s40168-019-0704-8.", "ArticleIdList": ["10.1186/s40168-019-0704-8", "PMC6567490", "31196177"]}, {"Citation": "McCoubrey L.E., Thomaidou S., Elbadawi M., Gaisford S., Orlu M., Basit A.W. Machine Learning Predicts Drug Metabolism and Bioaccumulation by Intestinal Microbiota. Pharmaceutics. 2021;13:2001. doi: 10.3390/pharmaceutics13122001.", "ArticleIdList": ["10.3390/pharmaceutics13122001", "PMC8707855", "34959282"]}], "ReferenceList": []}], "History": [{"Year": "2022", "Month": "8", "Day": "19"}, {"Year": "2022", "Month": "9", "Day": "29"}, {"Year": "2022", "Month": "10", "Day": "9"}, {"Year": "2022", "Month": "10", "Day": "27", "Hour": "1", "Minute": "25"}, {"Year": "2022", "Month": "10", "Day": "28", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "10", "Day": "29", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "10", "Day": "11"}], "PublicationStatus": "epublish", "ArticleIdList": ["36293657", "PMC9603471", "10.3390/ijerph192013076", "ijerph192013076"]}}], "PubmedBookArticle": []}